Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK2 | Q9HBH9 | 8/20 | 0.36 |
| ▸ | MYC | P01106 | 2/20 | 0.35 |
| ▸ | MAX | P61244 | 2/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.33 |
| ▸ | TRPV1 | Q8NER1 | 5/20 | 0.33 |
| ▸ | FBP1 | P09467 | 1/20 | 0.33 |
| ▸ | GCK | P35557 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2650121 | 0.95 | GCK (0.38) | MKNK2MYCMAXPTPN1TRPV1 | |
| SCHEMBL1343053 | 0.92 | MKNK2 (0.35) | MKNK2TRPV1FBP1GCK | |
| SCHEMBL1342930 | 0.91 | MYC (0.37) | MYCMAXPTPN1TRPV1FBP1 | |
| SCHEMBL2650118 | 0.90 | GCK (0.33) | MKNK2GCK | |
| SCHEMBL1341481 | 0.90 | SLC2A1 (0.36) | MYCMAXFBP1 | |
| SCHEMBL1342027 | 0.89 | MKNK2 (0.36) | MKNK2MYCMAXPTPN1TRPV1 | |
| SCHEMBL1342441 | 0.89 | MKNK2 (0.36) | MKNK2MYCMAXPTPN1TRPV1 | |
| SCHEMBL1343475 | 0.89 | GCK (0.42) | MKNK2MYCMAXPTPN1TRPV1 | |
| SCHEMBL1343001 | 0.88 | GRM4 (0.37) | MKNK2GCK | |
| SCHEMBL1342147 | 0.87 | GCK (0.43) | MKNK2MYCMAXPTPN1GCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8063081-B2 | N-(2-Phenoxyphenyl)-N'-(thiazol-2-yl)urea; glucokinase inhibitor; antidiabetic, hypoglycemic agent; activators of glucokinase | NOVO NORDISK A/S (DK) | 2011-11-22 | — | — | US | disclosed |
| US-7897628-B2 | {2-[3-(4-Methyl-2-[2-methypropoxy]phenyl)-ureido]-thiazol-4-yl}-acetic acid ethyl ester; glucokinase inhibitor; antidiabetic, hypoglycemic agent; activators of glucokinase | NOVO NORDISK A/S (DK) | 2011-03-01 | — | — | US | disclosed |
| US-20040122235-A1 | Aryl carbonyl derivatives as therapeutic agents | VTV THERAPEUTICS LLC | 2004-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122235-A1 | Aryl carbonyl derivatives as therapeutic agents | GCK, GCKR, PDK2 | MKNK2 469/4885MYC 180/4885MAX 2951/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.